Next Science Ltd traded at 0.85 this Tuesday July 5th, decreasing 0.01 or 0.59 percent since the previous trading session. Looking back, over the last four weeks, Next Science Ltd lost 10.46 percent. Over the last 12 months, its price fell by 46.52 percent. Looking ahead, we forecast Next Science Ltd to be priced at 0.77 by the end of this quarter and at 0.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.85
Daily Change
-0.59%
Yearly
-46.52%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Ansell 22.64 0.17 0.76% -43.63%
Fisher & Paykel Healthcare 18.50 0.54 3.01% -34.35%
Mayne Pharma 0.27 0.01 3.85% -19.40%
Nanosonics Ltd 3.59 0.02 0.56% -33.27%
Polynovo Ltd 1.47 0.14 10.11% -38.75%
ResMed 31.61 0.27 0.86% -2.08%


Next Science Ltd
Next Science Limited is an Australia-based medical technology company. The Company's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The Company's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.